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INTRODUCTION
The use of breast-conserving therapy (BCT) has increased as a 
definitive surgical treatment for early breast cancer patients, 
and BCT is performed in about 70% of breast cancer operations 
in Korea.1 The wide use of BCT is based on previous random-
ized trials showing favorable survival outcomes of BCT com-
pared to mastectomy.2-5 For this reason, in 1990, the National 
Institutes of Health (NIH) Consensus Development Conference 
on Treatment of Early-Stage Breast Cancer recommended BCT 
for the majority of women with early-stage breast cancer.6
In 2000, Perou, et al.7 determined the molecular subtypes of 
breast cancer, which were distinguished by differences in gene 
expression patterns. Breast cancer subtypes, classified accord-
ing to molecular phenotype, show different clinicopathological 
features and influence the prognosis and response to treat-
ment.8-13 Currently, immunohistochemistry (IHC)-based molec-
ular classification is used as a surrogate for gene expression 
profiling.9-11 Molecular subtyping based on IHC could provide a 
standard method for determining treatment and surveillance 
strategies in breast cancer patients.10,12,13
Among breast cancer subtypes, triple-negative breast cancer 
(TNBC), in which tumors are negative for estrogen receptor 
(ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) expression, has drawn substantial at-
tention due to its aggressive behavior, high risk of early relapse, 
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and poor overall survival (OS).12,13 There are no proven effective 
target therapies for the TNBC subtype of breast cancer, making 
it a clinical challenge for optimal patient management.14,15 Mul-
tiple studies showed a high risk of local recurrence after BCT in 
patients who had several clinical risk factors including specific 
molecular markers or gene expression patterns, such as those 
exhibited by the TNBC or HER2-enriched subtypes.16-20 Con-
versely, other studies have argued that BCT could safely replace 
mastectomy regardless of the breast cancer subtype.20-25 Thus, 
the use of BCT for TNBC is an ongoing concern for surgeons in 
this era of molecular subtyping for breast cancer. For this rea-
son, we compared the clinical outcomes between patients with 
TNBC and those with non-TNBC, both of whom underwent 
BCT, to evaluate the oncologic safety of BCT.
MATERIALS AND METHODS
Patient cohort
We used the Breast Cancer Registry database of Severance Hos-
pital, Yonsei University Health System to perform a retrospec-
tive analysis. The patient cohort consisted of 1533 women who 
underwent BCT due to primary breast cancer between 2000 
and 2010. Patients were excluded from the analysis if they re-
ceived neoadjuvant chemotherapy, presented with initial dis-
tant metastases, or had large-size tumors, non-epithelial-origin 
or special-type tumors (e.g., phyllodes tumor, lymphoma, sar-
coma, Paget’s disease, and inflammatory breast cancer), un-
available data on the type of surgery or radiotherapy, or un-
available data on the molecular subtype of a tumor distinguished 
as luminal type, HER2-enriched type, or TNBC. 
Patients with breast cancer received either BCT or mastecto-
my according to the operator’s decision, which involved the size, 
location, and multiplicity of the tumor and the patient’s prefer-
ence. Along with breast surgery, sentinel lymph node biopsy or 
standard level I/II axillary lymph node dissection was per-
formed. After surgery, all enrolled patients received adjuvant 
radiotherapy with a median boost dose of 10 Gy that covered 
the whole breast with or without the regional nodal area.26 Ad-
juvant endocrine therapy or chemotherapy was administered, 
if indicated. Criteria according to the sixth edition of the Ameri-
can Joint Committee on Cancer’s Cancer Staging Manual were 
used for TNM staging.27 Most HER2-positive tumors were not 
treated with neoadjuvant or adjuvant trastuzumab, as the use 
of trastuzumab was not sanctioned by the Korean National 
Health Insurance Service before 2009.
Patient characteristics including age, T stage, N stage, patho-
logic type, histologic grade, adjuvant hormone therapy, and ad-
juvant chemotherapy were reviewed. This study was reviewed 
and approved by the Institutional Review Board of Severance 
Hospital, Yonsei University Health System (IRB No. 4-2015-0132).
Tumor classification
Tumors with <10% ER/PR staining on IHC were considered to 
be ER/PR negative. We defined HER2-positive tumors as those 
with 3+ overexpression via immunohistochemical testing (IHC) 
or HER2 amplification via fluorescence in situ hybridization 
(FISH). Cases with HER2 expression levels of 0–1+ and 2+ with 
non-amplification via FISH were considered as HER2-negative.
We categorized breast cancer based on ER, PR, and HER2 sta-
tus, using the presence or absence of tumor markers via IHC or 
FISH as follows: TNBC (ER-, PR-, and HER2-negative) or non-
TNBC [either luminal type (ER- and/or PR-positive and any 
HER2 status) or HER2-enriched type (ER- and PR-negative and 
HER2-positive)]. Tumors that were ER- and PR-negative and 
HER2-unknown were excluded. Histological grade was assessed 
using the modified Bloom-Richardson classification.
Statistical analysis
Categorical variables were analyzed using the chi-square test or 
Fisher’s exact test, and continuous variables were analyzed us-
ing Student’s t-test. Locoregional recurrence-free survival (LRFS) 
was measured from the date of the definitive surgery to the date 
of the first documented locoregional recurrence. The OS was 
calculated from the date of the definitive surgery to the date of 
death. Death without any other identifiable cause was consid-
ered in the OS analysis. LRFS and OS were plotted using the Ka-
plan-Meier method and compared using the log-rank test.
Cox proportional hazard models were used for multivariate 
analyses to determine the association of the TNBC subtype with 
survival outcomes, after adjusting for potentially confounding 
variables.
p-values of <0.05 were considered statistically significant; all 
tests were two-sided. Statistical analyses were carried out using 
commercially available statistical software (SPSS Statistics 20, 
IBM, Chicago, IL, USA).
RESULTS
Clinicopathological characteristics of the patient 
groups
The number of breast cancer patients who received BCT at our 
institution increased between 2000 and 2010 (Supplementary 
Fig. 1, only online). BCT has been performed in half of all breast 
cancer operations since 2006.
Fig. 1 shows the proportion of molecular subtypes in BCT pa-
tients during the study period. From 2000, the proportions of 
TNBC and non-TNBC breast cancer patients who underwent 
BCT (≈20%) were similar.
Baseline characteristics of the patients and tumor classifica-
tion according to subtype are described in Table 1. Of 1533 tu-
mors, 1212 were non-TNBC, and 321 were of the TNBC subtype. 
The mean age of all patients was 48.7±9.5 years at diagnosis; 
however, the age distribution was different between the two 
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groups: the TNBC group had more young patients than the 
non-TNBC group. There were 51 patients (15.9%) younger than 
35 years of age in the TNBC group and 56 patients (4.6%) young-
er than 35 years of age in the non-TNBC group, respectively 
(p<0.001). The TNBC group had larger tumors (T2 37.4% vs. 
21.0%, p<0.001), fewer nodal metastases (N0 86.9% vs. 75.5%, 
p<0.001), and more tumors with a higher histological grade 
(Grade III 66.8% vs. 15.4%, p<0.001) than the non-TNBC group. 
The patients with TNBC had more tumors with other histologi-
cal types than the patients with non-TNBC (13.4% vs. 7.4%, 
p=0.001). In the non-TNBC group, approximately one in ten 
patients (10.7%) had ER-negative tumors, and one quarter of 
the patients (23.5%) had PR-negative (p<0.001) tumors. In ad-
dition, tumors from 216 non-TNBC cases were positive for am-
plification of HER2 (19.5%).
Adjuvant hormone therapy was administered to 1131 pa-
tients (93.3%) in the non-TNBC group compared to only 2.8% 
of patients in the TNBC group. More patients with TNBC re-
ceived adjuvant chemotherapy than patients with non-TNBC, 
and this difference was significant (87.9% vs. 60.0%, p<0.001). 
Clinical outcomes
The median follow-up period of all patients was 57 months 
(range 0–156). Figs. 2 and 3 illustrate the Kaplan-Meier plots of 
LRFS and OS comparing the two groups. Locoregional recur-
rence developed in seven cases (2.2%) with TNBC and in 28 
cases (2.3%) with non-TNBC, and this was not significantly dif-
ferent. LRFS for the TNBC group was comparable to the non-
TNBC group based on log-rank test results (5-year LRFS of 
TNBC vs. non-TNBC: 98.7% vs. 97.8%, p=0.63) (Fig. 2). Thirteen 
patients (4.0%) in the TNBC group and 39 patients (3.2%) in the 
non-TNBC group died during the follow-up period. The non-
TNBC group tended to show slightly better survival than the 
TNBC group; however, the difference was not statistically sig-
nificant (96.2% vs. 97.3%, p=0.72) (Fig. 3).
On multivariable analyses, the TNBC group did not show a 
significantly increased risk of locoregional recurrence and 
death compared to the non-TNBC group [hazard ratio (HR) for 
LRFS=0.37, 95% confidence interval (CI): 0.10–1.31; HR for 
OS=1.03, 95% CI: 0.31–3.39] (Table 2). Only the nodal stage in-
dependently affected OS, though it was not predictive of the 
prognosis of LRFS.
DISCUSSION
Based on several randomized-controlled trials, BCT has been 
proven to have clinical outcomes equivalent to mastectomy and 
has become the standard local treatment option for women 
with early-stage breast cancer.2-5 Given the aggressive features of 
TNBC, however, there is a concern that a more aggressive treat-
ment approach should be considered.15 The current study dem-
onstrated that clinical outcomes in terms of LRFS and OS in pa-
tients with TNBC who underwent BCT were not different from 
those with non-TNBC.
The use of BCT for breast cancer patients has increased sig-
nificantly at our institution since 2006. According to the Korean 
Breast Cancer Society (KBCS) registry data, while the propor-
tion of patients who underwent total mastectomy decreased 
from 71.2% in 2000 to 33.8% in 2011, the proportion of patients 
who underwent BCT surgery increased from 27.9% in 2000 to 
65.7% in 2011.1 These data are concordant with our results.
TNBC generally comprises 10–20% of breast cancers28 with a 
reported prevalence of 12.5% in a large, California population-
based study by Bauer, et al.,29 despite racial differences in the 
prevalence of TNBC.11,30 In agreement with these studies, our 
data showed a 10–20% proportion of TNBC in the breast cancer 
population, except for two years, 2000 and 2004. The data re-
garding the rates of locoregional recurrence and distant recur-
rence for TNBC patients with BCT are incongruent. In our study, 
the LRFS rates of TNBC and non-TNBC patients were not sig-
nificantly different; however, the OS rate of TNBC patients was 
slightly reduced until 6 years after the BCT, which might have 
been due to the aggressive behavior of TNBC. Interestingly, 
TNBC patients had a better clinical outcome if they survived 
longer than 6 years after treatment, compared to non-TNBC 
patients. After we adjusted for confounding factors in the prog-
nosis, such as age, stage, histologic grade, and systemic therapy, 
the multivariate analysis revealed that TNBC was unlikely to be 
an independent prognostic factor affecting the decision to un-
dergo BCT in breast cancer patients. This indicates that tumor 
subtype (TNBC or non-TNBC) alone does not influence LRFS 
in breast cancer patients with BCT. Similarly, Haffty, et al.25 
showed no difference in the ipsilateral breast relapse-free sur-
vival between the patients with TNBC and other subtypes with 
conservative management. Patients classified as TNBC were 
younger and had larger tumors than other subtypes yet had 
similar LN metastasis rates.25 The triple-negative subtype was 
Fig. 1. Molecular subtype proportions according to breast cancer sub-
type with breast-conserving therapy. TNBC, triple-negative breast can-
cer; HER2, human epidermal growth factor receptor 2. 
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an independent predictor of distant metastasis.25 In contrast, 
Arvold, et al.31 showed that TNBC patients had a significantly 
increased risk of local recurrence compared with luminal sub-
types. In addition, 91% of the patients in that study received ad-
juvant systemic therapy; the data were stratified according to 
the luminal subtype by histologic grade; and the study com-
pared five breast cancer subtypes and age quartiles and dem-
onstrated that young age remained an independent risk factor 
for locoregional recurrence.31 A similar study by Nguyen, et al.19 
also reported that the breast cancer subtype, as approximated 
based on ER, PR, and HER-2 status, was significantly associated 
with both local and distant recurrence after BCT. In that study, 
the luminal B and HER2-enriched subtypes had more instanc-
es of lymph node metastasis and lymphovascular invasion than 
TNBC, although the TNBC group had larger tumors and re-
ceived more chemotherapy.19 Meta-analysis of 22 studies by 
Wang, et al.20 reported that the TNBC subtype was associated 
with increased risks of both ipsilateral locoregional recurrence 
and distant metastasis compared to non-TNBC subtypes. In the 
TNBC cohort, however, patients who received BCT were less 
likely to develop ipsilateral locoregional recurrence and distant 
metastasis than those who underwent a mastectomy.20
In a previous study that compared the characteristic features 
of TNBC and other subtypes, the TNBC group was character-
Table 1. Baseline Patient and Tumor Characteristics
Baseline characteristics
Non-TNBC (n=1212) TNBC (n=321) All patients (n=1533)
p value*
n % n % n %
Age <0.001
≤35 56 4.6 51 15.9 107 7.0
>35 1156 95.4 269 84.1 1425 93.0
T stage <0.001
T1 957 79.0 201 62.6 1158 75.5
T2 255 21.0 120 37.4 375 24.5
N stage <0.001
N0 915 75.5 279 86.9 1194 77.9
N1 241 19.9 37 11.5 278 18.1
N2 42 3.5 5 1.6 47 3.1
N3 14 1.2 0 0.0 14 0.9
Histological type 0.001
Ductal 1079 89.0 274 85.4 1353 88.3
Lobular 43 3.5 4 1.2 47 3.1
Other 90 7.4 43 13.4 133 8.7
Histological grade <0.001
I 351 31.9 16 5.7 367 26.6
II 580 52.7 77 27.5 657 47.6
III 169 15.4 187 66.8 356 25.8
ER <0.001
Negative 130 10.7 321 100.0 451 29.4
Positive 1082 89.3 0 0.0 1082 70.6
PR <0.001
Negative 285 23.5 321 100.0 606 39.5
Positive 927 76.5 0 0.0 927 60.5
HER2 <0.001
Negative 892 80.5 321 100.0 1213 84.9
Positive 216 19.5 0 0.0 216 15.1
Hormone therapy <0.001
No 81 6.7 312 97.2 393 25.6
Yes 1131 93.3 9 2.8 1140 74.4
Adjuvant chemotherapy <0.001
No 485 40.0 39 12.1 524 34.2
Yes 726 60.0 282 87.9 1008 65.8
TNBC, triple-negative breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
*Non-TNBC vs. TNBC.
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ized by younger patients, larger and higher grade tumors, and 
more instances of lymph node metastasis.15 Our results showed 
that TNBC patients were younger, had larger tumors with a 
higher histologic grade than non-TNBC patients, and had clini-
copathological features that were similar to TNBC patients in 
prior studies, except in terms of lymph node metastasis. TNBC 
Fig. 2. Univariate analysis of locoregional recurrence-free survival after 
breast-conserving therapy according to TNBC and non-TNBC subtypes. 
TNBC, triple-negative breast cancer; LRFS, locoregional recurrence-free 
survival. 
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Fig. 3. Univariate analysis of overall survival after breast-conserving ther-
apy according to TNBC and non-TNBC subtypes. OS, overall survival; 
TNBC, triple-negative breast cancer.
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Table 2. Multivariate Analysis for Locoregional Recurrence-Free Survival and Overall Survival
Multivariate 
analysis 
Locoregional recurrence-free survival Overall survival
Hazard 
ratio
95% CI
p value
Hazard 
ratio
95% CI
p value
Lower Upper Lower Upper
Subtype
Non-TNBC Ref.  Ref.
TNBC 0.37 0.10 1.31 0.12 1.03 0.31 3.39 0.96 
Age
≤35 Ref. Ref.
>35 0.73 0.21 2.53 0.62 0.96 0.34 2.76 0.94
T stage
T1 Ref.  Ref.
T2 1.45 0.66 3.21  0.36 1.09 0.58 2.05 0.80
N stage
N0 Ref.  Ref.  
N+ 0.82 0.33 2.03 0.67 2.06 1.08 3.92 0.03 
Histological grade
I/II Ref.  Ref.
III 1.32 0.55 3.17 0.53 1.51 0.75 3.06 0.25 
Hormone therapy
No Ref.  Ref.
Yes 0.45 0.15 1.38 0.16 0.99 0.32 3.06 0.98 
Adjuvant chemotherapy
No Ref.  Ref.
Yes 0.72 0.30 1.75 0.47 1.26 0.53 2.99 0.60
TNBC, triple-negative breast cancer; CI, confidence interval.
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patients had less metastasis to the lymph nodes and underwent 
more adjuvant chemotherapy, which might have been respon-
sible for the better outcome of these patients. Dent, et al.15 also 
showed that TNBC had a more aggressive clinical course, 
though this feature was transient. These features of TNBC could 
support our result, which showed favorable outcomes for TNBC 
compared to non-TNBC after BCT.
However, there were limitations to the retrospective study de-
sign. First, as trastuzumab was approved for use by the Korean 
National Health Insurance only after the mid-2000s, testing for 
HER2 expression and prescribing trastuzumab were not rou-
tinely performed. Thus, there was a lack of information regard-
ing the administration of trastuzumab and HER2 evaluations in 
the registry prior to that time. Second, certain TNBC patients 
received hormone therapy. In the current study, about 2.8% of 
TNBC patients were treated with hormone therapy, and their 
tumors were weakly positive for hormone receptor expression 
(1–9%) on IHC. The tumors with weak hormone receptor posi-
tivity were regarded as negative. Whether the hormone recep-
tor positivity of 1–9% in these patients was real or an artifact has 
been disputed among many physicians.32 At our institution, hor-
mone receptor expression over 1% was considered as positive 
according to the guidelines from the American Society of Clini-
cal Oncology and the College of American Pathologists in 2010, 
which recommended a threshold of 1% or more for classifying 
breast cancer as ER-positive.33 Changes in the definition of the 
threshold of hormone receptor expression can influence clini-
cal outcomes.
The complexity of clinical, biological, and histopathological 
information on breast cancer creates difficulties for managing 
locoregional disease. Moreover, there are no specifıc locore-
gional treatment guidelines for TNBC.34 However, this study 
showed non-inferior locoregional recurrence in patients with 
early TNBC and comparable outcomes between TNBC and non-
TNBC. Our findings support the hypothesis that BCT is an ac-
ceptable surgical approach in patients with TNBC.
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